Ocugen Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
0.83
0.02
(2.47%)
Volume:
4,917,760
52 week range:
0.52 - 1.98
Market Cap:
242.386M
Company Description:
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis. OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD) and OCU200, is in preclinical development stage.